Active, not recruitingPhase 3NCT06672237
A Phase 3 Study of NTLA-2001 in ATTRv-PN
Studying Hereditary amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Intellia Therapeutics
- Intervention
- nexiguran ziclumeran(biological)
- Enrollment
- 50 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2024 – 2028
Study locations (16)
- Hospital Británico de Buenos Aires, Buenos Aires, Argentina
- Hospital Italiano de Buenos Aires (HIBA), Buenos Aires, Argentina
- Hospital El Cruce, San Juan Bautista, Argentina
- Westmead Hospital, Westmead, Australia
- Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil
- HCFMRP - Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto, Ribeirão Preto, Brazil
- Instituto de Educacao, Pesquisa e Gestao em Saude, Rio de Janeiro, Brazil
- PSEG Centro de Pesquisa Clinica S.A., São Paulo, Brazil
- National Institute of Medical Sciences and Nutrition - Salvador Zubiran (INCMNSZ), Tlalpan, Mexico
- New Zealand Clinical Research, Auckland, New Zealand
- National University Hospital, Singapore, Singapore
- Singapore General Hospital, Singapore, Singapore
- National Taiwan University Hospital, Taipei, Taiwan
- Taipei Veterans General Hospital, Taipei, Taiwan
- Chang Gung Medical Foundation - Linkou Branch, Taoyuan District, Taiwan
- +1 more locations on ClinicalTrials.gov
Collaborators
Regeneron Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06672237 on ClinicalTrials.govOther trials for Hereditary amyloidosis
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07124377Phenotypic Manifestations of Hereditary ATTR AmyloidosisHospital 9 de Julio de Las Breñas
- RECRUITINGNCT06251778NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on TafamidisPaolo Milani
- RECRUITINGPHASE2NCT05758493Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic AmyloidosisOregon Health and Science University